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Mature lymphoidmalignancies are themost common hematologi-
cal cancers, with approximately 93,500 B non-Hodgkin lympho-
mas (NHL), 17,500 Hodgkin lymphomas, 14,000 chronic
lymphocytic leukemia (CLL), and 3300 T-NHL new cases being
diagnosed every year in Europe.1,2 Their optimal management
requires integrated morphological and immunophenotypic analy-
sis of cell and tissue, together with chromosome and molecular
analyses. The standardization of these techniques has improved
their reproducibility and consequently their inclusion in evolving
classiﬁcations of mature lymphoid malignancies.3
High throughput sequencing techniques provide useful diag-
nostic, prognostic, and theranostic information for the individual-
ized clinical management of patients with mature lymphoid
malignancies, but much controversy exists regarding panel design.
Inorder to harmonize sequencing panels for clinical use, the French
LYSA (LYmphoma Study Association) and GBMHM (Groupe de
Biologistes Moléculaires des Hémopathies Malignes) cooperative
groups established consensus minimal panels for B and T lineage
lymphomas, which are presented here. An earlier, French-
language, versionof this consensus has beenpublishedpreviously.4
The arrival of high throughput next-generation sequencing
(NGS) techniques represents a new opportunity but also a new
challenge for the diagnosis of lymphoid malignancies.5 Com-
pared to polymerase chain reaction and Sanger sequencing, it
comes with additional speciﬁcities.
Spatial and temporal heterogeneity
While the histological appearance of most cancers is relatively
homogeneous, regardless of the biopsy site, there is considerably
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more intraindividual molecular variability.6,7 Similarly, longitu-
dinal studies have conﬁrmed the suspected Darwinian evolution
of cancer, with temporal evolution in clonal architecture.8 NGS
has considerably improved our ability to detect subclonal
alterations compared with Sanger sequencing (detection thresh-
old around 10%), as long as sufﬁcient sequencing depth is
achieved (at least 500 reads/speciﬁc nucleotide). However, the
analysis of the spatial heterogeneity requires the analysis of
sample DNA from different sites, which is now achievable by
analysis of circulating tumor (ct) DNA. The analysis of ct-DNA
by NGS is a noninvasive procedure, which might also provide
important prognostic information with longitudinal follow-up.9
Difﬁculties in interpreting variants
Pioneering studies in tumor oncogenesis were based on a
relatively simple model whereby molecular alterations were
necessary and sufﬁcient for malignant transformation.10 Several
observations suggest that this is an over-simpliﬁcation, such as
the existence of cancers with no apparent recurrent mutation11 or
the disappointing results of targeted therapy based only on
molecular abnormalities.12,13 This implies that a molecular
abnormality must be interpreted in its global context, including
the (WHO deﬁned) histological subtype, immunophenotype, and
somatic genetic structural and numerical abnormalities.3 Of note,
in routine clinical practice, most of the NGS tumor analyses are
not paired with analysis of constitutional genome, meaning that
the somatic nature of the mutations is not formally demonstrated.
Technical difﬁculties
The validity of NGS results depends on the quality of the nucleic
acids and their preanalytic treatment, particularly but not
exclusively, tissue ﬁxation. For example, sequencing errors can
be due to cytosine deamination during formol ﬁxation and
parafﬁn embedding.14,15 It is consequently preferable, whenever
possible, to work with fresh frozen tissue or extemporaneously
extracted DNA. Each NGS step can inﬂuence the results: nucleic
acid extraction techniques, library constitution and enrichment,
sequencing technologies, internal quality controls, bioinformatic
ﬁltering, and biological interpretation. The existence of several
NGS platforms allows the comparison of different approaches,
but also makes harmonization and standardization indispens-
able, in order to provide homogeneous, reliable results
throughout Europe. The Harmony program (https://www.
harmony-alliance.eu) is developing Europe-wide databases of
clinical and biological data, including NGS results. It is of
paramount importance that the molecular data submitted to
Harmony have been proven to be reproducible, via participation
of the providers in national or European external quality
assessment (EQA) programs, ideally in combination with
continuing medical education (CME). Whether such EQA/
CME should be national or European depends on the frequency
of the analysis and practical logistics. As examples, the European
Euro-MRD (http://www.euromrd.org) group, a member of the
ESLHO (http://www.eslho.org) EHA-scientiﬁc working group
(https://ehaweb.org/research/scientiﬁc-working-groups/) organ-
izes EQA/CME for immunogenetic quantiﬁcation of Minimal
Residual Disease quantiﬁcation in lymphoid malignancies, the
UK NEQUAS system (https://ukneqas.org.uk) organizes stand-
alone EQA for many molecular tests and the aforementioned
French GBMHM (https://sites.google.com/site/gbmhmassocia
tion/home) organizes national EQA/CME for the most common
molecular tests in hematological malignancies, including lym-
phoid and myeloid NGS. The increasing interaction between
EHA scientiﬁc working groups will facilitate harmonized,
optimized approaches to EQA and CME.
NGS panel choice
In addition to technological considerations, the choice of target
genes or panels is a crucial step in the development of appropriate
diagnostic approaches. Although the availability of genome wide
(whole-genome or whole-exome) approaches will become
increasingly available, targeted analyses allow optimization of
quality (read depth, variant characterization, reporting timelines,
etc.), and cost, and are a pragmatic option for lymphoma
diagnostics in the foreseeable future. An optimal panel must reply
to diagnostic (both positive and differential), prognostic and
theranostic requirements for the different lymphoma subtypes,
while remaining sufﬁciently simple to allow for uniform
application.
An exhaustive literature search was performed by a duo of
clinical/molecular experts for each of the principal mature
lymphoid subtypes. These included: diffuse large B cell lympho-
ma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma,
marginal zone lymphoma (MZL), hairy cell lymphoma (HCL),
lymphoplasmocytic lymphoma, Waldenström macroglobuline-
mia (WM), and CLL for B cell malignancies. T cell subtypes
included angioimmunoblastic T cell lymphoma (AITL) and other
nodal lymphomas derived from T Follicular helper cells (TFH-
PTCL), peripheral T cell lymphoma—not-otherwise speciﬁed,
anaplastic large cell lymphoma, intestinal T lymphomas
associated with an enteropathy or not (monomorphic epithelial
intestinal T lymphoma), hepatosplenic T lymphoma, nasal type
extranodal NK/T lymphoma, Sezary syndrome, adult T cell
lymphoma/leukemia, large granular lymphocytes leukemia, and
T prolymphocytic leukemia. For each of these entities, genes
found to be mutated or affected by copy number variation (CNV)
inmore than 5%of cases were noted. The chromosomal location,
number of exons, and known function were noted for each gene,
as were the frequency of mutations (gain or loss of function,
hotspot or diffuse) and CNV in each of the aforementioned
entities. Finally, a clinical relevance score was attributed to each
category (Table 1).
It is to be noted that this process was undertaken prior to
publication of the joint Association for Molecular Pathology,
American College of Medical Genetics and Genomics, American
Society of Clinical Oncology, and College of American
Pathologists’ recommendations16 and did not use strictly
identical criteria. Our score 2 corresponds to their “Tier 1”
recommendations, score 1 to “Tier 2” and our score 0 to “Tiers 3
and 4.”
This generated a compiled list of genes, which was circulated to
GBMHM and LYSA experts for each disease subtype, who
selected a minimal panel for their disease entity. The individual
Table 1
Clinical Relevance Scores
0 1 2
Diagnostic interest None Partial Marked (pathognomonic mutation)
Pronostic interest None Potential Conﬁrmed (in at least 2 studies)
Theranostic interest None Potential Conﬁrmed (companion diagnostics)
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panels were then compared in order to select 2 consensus panels
for mature B and T lymphoid disorders.
Among the numerous recurrent molecular abnormalities
identiﬁed in mature lymphoid malignancies, 95 were considered
to be of at least potential interest in one of the diagnostic/
prognostic/theranostic categories and 29 to be of conﬁrmed
interest (score 2). As such, genes such as KMT2D/MLL2,
although frequently mutated in mature B cell malignancies, were
not selected due to the lack of clear evidence of their clinical
signiﬁcance, in order to maintain the number of selected genes
within the limits of a panel to be used by most diagnostic
sequencing platforms. ATM was also excluded because of its size
and the difﬁculty in distinguishing somatic and germline
mutations in the absence of analysis of nontumor DNA.
Because there was little overlap in the selected genes in mature B
and T cell malignancies, we chose to separate the 2 panels, with
laboratories being left free to use them in independent or combined
libraries, depending on local priorities, constraints, and technical
choices, such as capture versus amplicon approaches.
Aﬁnalpanelof33geneswas identiﬁedforBcell lymphomas(Fig.1
and Supplemental Table 1, Supplemental Digital Content 1, http://
links.lww.com/HS/A21)andapanelof11genesforTcell lymphomas
(Fig. 2 and Supplemental Table 2, Supplemental Digital Content 2,
http://links.lww.com/HS/A22). This corresponds to approximately
504 exons for the B cell panel and 190 exons for theT cell panel if an
exhaustive approach of analysis of all exons and nontranslated
regions is chosen and239 and107 exons, respectively, if a restrictive
approach covering only known mutation hotspots is adopted.
Genes of positive or differential diagnostic interest
As for most cancers, pathognomonic mutations are exceedingly
rare in lymphoma, even if some molecular abnormalities are
much more frequent in certain subtypes, thus representing useful
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Figure 1. A heatmap representation of the prevalence of gene alterations in mature B lymphoid malignancies from the LYSA/GBMHM consensus
panel. The ∗ symbol for CDKN2A underlines that this locus is altered by deletions (and not mutations). The borders of the squares are colored when the alteration
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diagnostic markers. This is well recognized for the BRAF V600E
mutation in HCL, the SF3B1 K700E mutation in CLL, or the
MYD88 L265P mutation in WM. In mature T lymphomas,
RHOA (G17V), IDH2 (R172), andTET2mutations are strongly
associated with AITL and TFH-PTCL. In less clear-cut situations,
mutational proﬁles should be interpreted in conjunction with
other parameters, ideally within multidisciplinary tumor boards.
Figure 1 is a graphic representation of the frequency of alterations
in the 33 genes of the B cell panel in the different subgroups of
mature B cell malignancies and Figure 2 shows equivalent data
for the 11 genes of the T cell panel.
Genes with prognostic interest
The inﬂuence of mutation proﬁles on prognostic evaluation is
evolving rapidly, partly due to evolving therapeutic practice.
Examples in mature lymphoid malignancies include the m7 FLIPI
score in FL17,18 or NOTCH1, SF3B1, and TP53 mutations in
CLL, used in combination with cytogenetic abnormalities.19
Recent examples of NGS approaches with prognostic value
include a complement to ABC/GCB subtyping of DLBCL,20–22
illustrating the need to update this type of panel regularly.
Genes of theranostic interest
This category includes genes whose mutational status already
determines the choice of therapy, such as the use of ibrutinib in
TP53-mutated CLL, and others which are likely to do so soon.
The latter category includes targets such as EZH223 in FL, or
CXCR4 in WM.24 It also includes genes for which mutations are
selected in the presence of certain targeted treatments, such as
BTK, PLCG2, or genes activating the alternative NF-kB pathway
(BIRC3, TRAF2, TRAF3) in patients treated by ibrutinib.25,26 In
T cell lymphomas, a biological rationale could justify treatment
based on mutational proﬁles, such as the use of demethylating
agents for lymphomas with epigenetic deregulation evidenced by
mutations of TET2,27DNMT3A, and/or IDH2), or the use of
speciﬁc IDH2 inhibitors, although this would obviously require
prior rigorous evaluation.
Perspectives
The rapid advances in our understanding of the impact of somatic
mutation in lymphoid malignancies will make regular updating
of consensus panels obligatory. The objectives of a given panel
should also be borne inmind, since a limited “universal” panel, as
described here, cannot replace more speciﬁc, extensive panels as,
for example, recently described for DLBCL prognostic evalua-
tion.21,22 The capacity of panels to evolve over time is also
dependent on the technology used, with capture approaches
evolving more easily than amplicon approaches.
The minimal panel described here is designed for platforms
analyzing a wide variety of lymphoid disorders and can be
complemented by additional targets of local interest, as long as
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such inclusion does not impact detection of the core target genes.
Identiﬁcation of a common core of minimal targets, and their
diffusion and adoption by molecular diagnostic platforms
providing results for cooperative clinical studies and for
standardized patient care is important because it will allow:
(a) external quality assessment of common targets;
(b) the use of these targets for medico-economic evaluation of
NGS techniques; and
(c) the realization of retrospective national or international
cooperative group studies using reproducible results, which
have been proven to be robust in amulticenter setting through
EQA programs.
The “universal” orientation panel described here could be
considered excessive or inappropriate for routine hospital
practice. One alternative would be development of a European
network of reference laboratories for each subtype of lymphoid
malignancy, who would perform more in-depth molecular
analyses based on results of an even more restricted primary,
local “universal lymphoid” NGS panel (or on initial orientation
based purely on cell/tissue morphology and immunophenotype).
Practical considerations such as reporting delays and the number
of samples recruited by a given platform are important when
deciding the most appropriate European set-up.
Reimbursement for NGS diagnostics in Europe varies
signiﬁcantly between European countries, with most undertaking
to develop suitable models. In France, it is currently based on the
volume sequenced, but more appropriate economic models that
take into account variable transmission of results, depending on
the clinical context, need to be developed. Medico-economic
evaluation requires integration of consolidated costs (which are
heavily dependent on the frequency of realization of a given
panel), the impact of NGS on reduced use of classical tests and the
therapeutic implications of more precise diagnostics. Assuming a
unit cost of 600€/test and analysis of one-third of the 128,500
new cases of lymphoma and CLL, the global cost of diagnostic
NGS in Europe (with no follow-up or relapse analysis) would be
approximately 25 M€. It should, however, be emphasized that
restricting use of innovative, costly, therapies on the basis of
companion diagnostic identiﬁcation of patients most likely to
beneﬁt can easily be cost-effective. These considerations clearly
illustrate the need for appropriate guidelines for innovative tests
and close clinical and laboratory interaction.
Patients requiring NGS analyses could be selected by a
reference center after pluri-disciplinary tumor board evaluation
of clinical, histological/morphological, immunophenotypic, cy-
togenetic, and molecular results and restricted to cases:
- with diagnostic difﬁculties;
- for prognostic evaluation when appropriate panels exist (most
likely within the context of prospective cooperative multicenter
trials);
- with theranostic intent when the mutation status determines use
of speciﬁc treatment, once again within the context of clinical
trials and preferentially in relapsing/resistant patients.
It is important to emphasize that the attempt at harmonization
of NGS panels described here must be accompanied by the use of
standardized bioinformatics pipelines, preferably independent of
those proposed by the sequencing platform manufacturers (often
heterogeneous and poorly adapted to speciﬁc requirements), in
order to optimize intercenter reporting reproducibility. Filtering
of constitutional variants, the advantages, and inconveniences of
different databases, cutoffs for variant allelic reporting and
criteria for CNVs all need to be taken into consideration.28 Their
harmonization will allowNGS results from different platforms to
be exploited for individual patients.
Conclusions
The harmonization of diagnostic practice and quality control is a
prerequisite for equal access to diagnostic precision across
Europe. The consensus panel described here complements this
approach by encouraging widespread use of a minimum set of
shared targets for mature lymphoid malignancies. This will
encourage interaction between different molecular genetic
centers. While a minimal consensus panel is inevitably rapidly
outdated, this approach provides a stepping stone to a common
NGS language within mature lymphoid malignancies between
platforms within and between countries.
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